Drugs / fluvestrant
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06133088 | Aug 2023 → Dec 2024 | Her2-receptor negative breast cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03939871 | Dec 2017 → Dec 2020 | hormone receptor-positive breast cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fluvestrant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06133088 ↗ |
| Route | Intramuscular | “Fluvestrant: administered at a dose of 0.5g once im every 28 days” NCT03939871 ↗ |